jpi-289
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT01983358)
Timeline
Indications
Studied for
Mechanism of action
- Poly [ADP-ribose] polymerase-1INHIBITOR
PARP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jpi-289
- jpi-289
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03062397 | Phase 2 | Nov 1, 2016 | Jeil Pharmaceutical Co., Ltd. |
| NCT02396069 | Phase 1 | Mar 1, 2015 | Jeil Pharmaceutical Co., Ltd., University of Ulsan |
| NCT01983358 | Phase 1 | Nov 1, 2013 | AIDS Malignancy Consortium, Jeil Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jeil Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2013 |
| AIDS Malignancy Consortium | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1